Literature DB >> 26320252

Inhibitory FcγRIIb-Mediated Soluble Antigen Clearance from Plasma by a pH-Dependent Antigen-Binding Antibody and Its Enhancement by Fc Engineering.

Yuki Iwayanagi1, Tomoyuki Igawa2, Atsuhiko Maeda1, Kenta Haraya1, Naoko A Wada1, Norihito Shibahara1, Ken Ohmine1, Takeru Nambu1, Genki Nakamura1, Futa Mimoto1, Hitoshi Katada1, Shunsuke Ito1, Tatsuhiko Tachibana1, Kou-ichi Jishage1, Kunihiro Hattori1.   

Abstract

Fc engineering can modulate the Fc-FcγR interaction and thus enhance the potency of Abs that target membrane-bound Ags, but it has not been applied to Abs that target soluble Ags. In this study, we revealed a previously unknown function of inhibitory FcγRII in vivo and, using an Ab that binds to Ag pH dependently, demonstrated that the function can be exploited to target soluble Ag. Because pH-dependent Ab dissociates Ag in acidic endosome, its Ag clearance from circulation reflects the cellular uptake rate of Ag/Ab complexes. In vivo studies showed that FcγR but not neonatal FcR contributes to Ag clearance by the pH-dependent Ab, and when Fc binding to mouse FcγRII and III was increased, Ag clearance was markedly accelerated in wild-type mice and FcR γ-chain knockout mice, but the effect was diminished in FcγRII knockout mice. This demonstrates that mouse FcγRII efficiently promotes Ab uptake into the cell and its subsequent recycling back to the cell surface. Furthermore, when a human IgG1 Fc variant with selectively increased binding to human FcγRIIb was tested in human FcγRIIb transgenic mice, Ag clearance was accelerated without compromising the Ab half-life. Taken together, inhibitory FcγRIIb was found to play a prominent role in the cellular uptake of monomeric Ag/Ab immune complexes in vivo, and when the Fc of a pH-dependent Ab was engineered to selectively enhance human FcγRIIb binding, the Ab could accelerate soluble Ag clearance from circulation. We assume such a function would enhance the therapeutic potency of Abs that target soluble Ags.
Copyright © 2015 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26320252      PMCID: PMC4574519          DOI: 10.4049/jimmunol.1401470

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  34 in total

1.  Properties of a general PK/PD model of antibody-ligand interactions for therapeutic antibodies that bind to soluble endogenous targets.

Authors:  Jasmine P Davda; Ryan J Hansen
Journal:  MAbs       Date:  2010-09-01       Impact factor: 5.857

2.  Cell surface recycling of internalized antigen permits dendritic cell priming of B cells.

Authors:  Amy Bergtold; Dharmesh D Desai; Anamika Gavhane; Raphael Clynes
Journal:  Immunity       Date:  2005-11       Impact factor: 31.745

3.  Divergent immunoglobulin g subclass activity through selective Fc receptor binding.

Authors:  Falk Nimmerjahn; Jeffrey V Ravetch
Journal:  Science       Date:  2005-12-02       Impact factor: 47.728

4.  Composition and biologic properties of soluble IgG-anti-IgG immune complexes: effects of variations in the specificity of rabbit antibodies to different structural components of human IgG.

Authors:  W P Arend; J C Sturge
Journal:  J Immunol       Date:  1979-07       Impact factor: 5.422

5.  Neonatal Fc receptor for IgG (FcRn) regulates cross-presentation of IgG immune complexes by CD8-CD11b+ dendritic cells.

Authors:  Kristi Baker; Shuo-Wang Qiao; Timothy T Kuo; Victoria G Aveson; Barbara Platzer; Jan-Terje Andersen; Inger Sandlie; Zhangguo Chen; Colin de Haar; Wayne I Lencer; Edda Fiebiger; Richard S Blumberg
Journal:  Proc Natl Acad Sci U S A       Date:  2011-05-31       Impact factor: 11.205

6.  Fc receptors are required in passive and active immunity to melanoma.

Authors:  R Clynes; Y Takechi; Y Moroi; A Houghton; J V Ravetch
Journal:  Proc Natl Acad Sci U S A       Date:  1998-01-20       Impact factor: 11.205

7.  A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis.

Authors:  Jasper J Haringman; Danielle M Gerlag; Tom J M Smeets; Dominique Baeten; Filip van den Bosch; Barry Bresnihan; Ferdinand C Breedveld; Huib J Dinant; Francois Legay; Hermann Gram; Pius Loetscher; Robert Schmouder; Thasia Woodworth; Paul P Tak
Journal:  Arthritis Rheum       Date:  2006-08

8.  Comparison of GK1.5 and chimeric rat/mouse GK1.5 anti-CD4 antibodies for prolongation of skin allograft survival and suppression of alloantibody production in mice.

Authors:  A Rashid; H Auchincloss; J Sharon
Journal:  J Immunol       Date:  1992-03-01       Impact factor: 5.422

9.  Characterization of monoclonal antibodies to Treponema pallidum.

Authors:  S A Lukehart; M R Tam; J Hom; S A Baker-Zander; K K Holmes; R C Nowinski
Journal:  J Immunol       Date:  1985-01       Impact factor: 5.422

Review 10.  Of mice and men: the need for humanized mouse models to study human IgG activity in vivo.

Authors:  Anja Lux; Falk Nimmerjahn
Journal:  J Clin Immunol       Date:  2012-09-05       Impact factor: 8.317

View more
  14 in total

1.  Elimination of plasma soluble antigen in cynomolgus monkeys by combining pH-dependent antigen binding and novel Fc engineering.

Authors:  Yuji Hori; Ken Ohmine; Hitoshi Katada; Yuki Noguchi; Kazuki Sato; Takeru Nambu; Lam Runyi Adeline; Gan Siok Wan; Kenta Haraya; Kazuhisa Ozeki; Masahiko Nanami; Tatsuhiko Tachibana; Zenjiro Sampei; Taichi Kuramochi; Junichi Nezu; Kunihiro Hattori; Tomoyuki Igawa
Journal:  MAbs       Date:  2022 Jan-Dec       Impact factor: 6.440

2.  Identification of human IgG1 variant with enhanced FcRn binding and without increased binding to rheumatoid factor autoantibody.

Authors:  Atsuhiko Maeda; Yuki Iwayanagi; Kenta Haraya; Tatsuhiko Tachibana; Genki Nakamura; Takeru Nambu; Keiko Esaki; Kunihiro Hattori; Tomoyuki Igawa
Journal:  MAbs       Date:  2017-04-07       Impact factor: 5.857

3.  Entire CD3ε, δ, and γ humanized mouse to evaluate human CD3-mediated therapeutics.

Authors:  Otoya Ueda; Naoko A Wada; Yasuko Kinoshita; Hiroshi Hino; Mami Kakefuda; Tsuneo Ito; Etsuko Fujii; Mizuho Noguchi; Kiyoharu Sato; Masahiro Morita; Hiromi Tateishi; Kaoru Matsumoto; Chisato Goto; Yosuke Kawase; Atsuhiko Kato; Kunihiro Hattori; Junichi Nezu; Takahiro Ishiguro; Kou-Ichi Jishage
Journal:  Sci Rep       Date:  2017-04-03       Impact factor: 4.379

4.  Targeted Fcγ Receptor (FcγR)-mediated Clearance by a Biparatopic Bispecific Antibody.

Authors:  Srinath Kasturirangan; G Jonah Rainey; Linda Xu; Xinwei Wang; Alyse Portnoff; Tracy Chen; Christine Fazenbaker; Helen Zhong; Jared Bee; Zhutian Zeng; Craig Jenne; Herren Wu; Changshou Gao
Journal:  J Biol Chem       Date:  2017-01-18       Impact factor: 5.157

Review 5.  Pharmacokinetic and Pharmacodynamic Considerations in the Design of Therapeutic Antibodies.

Authors:  Douglas Leipold; Saileta Prabhu
Journal:  Clin Transl Sci       Date:  2018-12-27       Impact factor: 4.689

Review 6.  The Human FcγRII (CD32) Family of Leukocyte FcR in Health and Disease.

Authors:  Jessica C Anania; Alicia M Chenoweth; Bruce D Wines; P Mark Hogarth
Journal:  Front Immunol       Date:  2019-03-19       Impact factor: 7.561

7.  Novel myostatin-specific antibody enhances muscle strength in muscle disease models.

Authors:  Hiroyasu Muramatsu; Taichi Kuramochi; Hitoshi Katada; Atsunori Ueyama; Yoshinao Ruike; Ken Ohmine; Meiri Shida-Kawazoe; Rie Miyano-Nishizawa; Yuichiro Shimizu; Momoko Okuda; Yuji Hori; Madoka Hayashi; Kenta Haraya; Nobuhiro Ban; Tatsuya Nonaka; Masaki Honda; Hidetomo Kitamura; Kunihiro Hattori; Takehisa Kitazawa; Tomoyuki Igawa; Yoshiki Kawabe; Junichi Nezu
Journal:  Sci Rep       Date:  2021-01-25       Impact factor: 4.379

Review 8.  Expanding horizons in complement drug discovery: challenges and emerging strategies.

Authors:  Claire L Harris
Journal:  Semin Immunopathol       Date:  2017-10-06       Impact factor: 9.623

Review 9.  Harnessing the immune system via FcγR function in immune therapy: a pathway to next-gen mAbs.

Authors:  Alicia M Chenoweth; Bruce D Wines; Jessica C Anania; P Mark Hogarth
Journal:  Immunol Cell Biol       Date:  2020-04-12       Impact factor: 5.126

10.  Antibody engineering to generate SKY59, a long-acting anti-C5 recycling antibody.

Authors:  Zenjiro Sampei; Kenta Haraya; Tatsuhiko Tachibana; Taku Fukuzawa; Meiri Shida-Kawazoe; Siok Wan Gan; Yuichiro Shimizu; Yoshinao Ruike; Shu Feng; Taichi Kuramochi; Masaru Muraoka; Takehisa Kitazawa; Yoshiki Kawabe; Tomoyuki Igawa; Kunihiro Hattori; Junichi Nezu
Journal:  PLoS One       Date:  2018-12-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.